Skip to main content

Advertisement

SpringerLink
Log in

Interstitial single fraction brachytherapy for malignant pulmonary tumours

  • Original Article
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

Abstract

Purpose

Interstitial brachytherapy for pulmonary tumours is an alternative to stereotactic radiotherapy, allowing high conformity despite it being an invasive technique. The aim of the study was the analysis of dose distribution, toxicity and tumour response rates.

Methods

In the years 2014–2019, 27 patients with pulmonary tumours received 36 interstitial brachytherapies with Ir-192: 11 patients with non-small cell lung cancer, 16 patients with pulmonary metastases of other entities.

Results

Patients were treated with a median (interquartile range) prescription dose of 20 (20–26) Gy in a single fraction. Mean lung dose to the ipsilateral lung was 2.8 (1.6–4.7) Gy. Maximum doses to the heart, oesophagus, thoracic wall and spinal cord were 2.4 (1.8–4.6) Gy, 2.0 (1.2–6.2) Gy, 12.6 (8.0–18.2) Gy and 1.5 (0.6–3.9) Gy.

Median survival after treatment was 15 months, with a 1- and 2‑year local control of 84% and 60%. Median overall survival after initial cancer diagnosis was 94 months; 2 years following brachytherapy, 75% of patients with colorectal cancer vs. 37% with other histologies were alive; p = 0.14.

In 69% (n = 25), brachytherapy could be performed without acute complications. A self-limiting bleeding occurred in 8% (n = 3), fever in 3% (n = 1), pneumothorax in 17% (n = 6), and pulmonary failure in 3% (n = 1). Patients with > 20 Gy in 95% of planning target volume had higher pneumothorax rates needing intervention (31% vs. 5%, p = 0.04).

Conclusions

Interstitial brachytherapy for pulmonary tumours is a highly conformal therapy with minimal doses to the organs at risk. For the majority of patients, treatment can be performed without relevant complications in a single fraction with a satisfactory local control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gomez DR, Tang C, Zhang J et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37:1558–1565

    Article  CAS  Google Scholar 

  2. Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4:e173501

    Article  Google Scholar 

  3. Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058

    Article  Google Scholar 

  4. Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830–2838. https://doi.org/10.1200/JCO.20.00818

    Article  PubMed  Google Scholar 

  5. Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637

    Article  Google Scholar 

  6. Loi M, Franceschini D, Dominici L et al (2020) Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. Strahlenther Onkol. https://doi.org/10.1007/s00066-020-01687-9

    Article  PubMed  Google Scholar 

  7. Nicosia L, Cuccia F, Mazzola R et al (2020) Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol 196:813–820

    Article  Google Scholar 

  8. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10

    Article  CAS  Google Scholar 

  9. Tselis N, Ferentinos K, Kolotas C et al (2011) Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol 6:545–552

    Article  Google Scholar 

  10. Guckenberger M, Baus WW, Blanck O et al (2020) Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol 196:417–420

    Article  Google Scholar 

  11. Youroukou A, Gkiozos I, Kalaitzi Z et al (2017) The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review. Clin Transl Oncol 19:945–950

    Article  CAS  Google Scholar 

  12. Chatzikonstantinou G, Zamboglou N, Archavlis E et al (2018) CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. Strahlenther Onkol 194:1171–1179

    Article  Google Scholar 

  13. Chatzikonstantinou G, Zamboglou N, Baltas D, Ferentinos K, Bon D, Tselis N (2019) Image-guided interstitial high-dose-rate brachytherapy for dose escalation in the radiotherapy treatment of locally advanced lung cancer: a single-institute experience. Brachytherapy 18:829–834

    Article  Google Scholar 

  14. Mohnike K, Neumann K, Hass P et al (2017) Radioablation of adrenal gland malignomas with interstitial high-dose-rate brachytherapy: efficacy and outcome. Strahlenther Onkol 193:612–619

    Article  CAS  Google Scholar 

  15. Pech M, Wieners G, Kryza R et al (2008) CT-guided brachytherapy (CTGB) versus interstitial laser ablation (ILT) of colorectal liver metastases: an intraindividual matched-pair analysis. Strahlenther Onkol 184:302–306

    Article  Google Scholar 

  16. Peters N, Wieners G, Pech M et al (2008) CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlenther Onkol 184:296–301

    Article  Google Scholar 

  17. Hass P, Mohnike K, Kropf S et al (2019) Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy 18:823–828

    Article  Google Scholar 

  18. Chan MK, Lee VW, Kadoya N et al (2018) Single fraction computed tomography-guided high-dose-rate brachytherapy or stereotactic body radiotherapy for primary and metastatic lung tumors? J Contemp Brachytherapy 10:446–453

    Article  Google Scholar 

  19. Le QT, Loo BW, Ho A et al (2006) Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 1:802–809

    Article  Google Scholar 

  20. Morias S, Marcu LG, Short M et al (2018) Treatment-related adverse effects in lung cancer patients after stereotactic ablative radiation therapy. J Oncol 2018:6483626

    Article  Google Scholar 

  21. Ricke J, Wust P, Wieners G et al (2005) CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest 127:2237–2242

    Article  Google Scholar 

  22. Hosten N, Stier A, Weigel C et al (2003) Laser-induced thermotherapy (LITT) of lung metastases: description of a miniaturized applicator, optimization, and initial treatment of patients. Rofo 175:393–400

    Article  CAS  Google Scholar 

  23. Steinke K, Sewell PE, Dupuy D et al (2004) Pulmonary radiofrequency ablation—an international study survey. Anticancer Res 24:339–343

    PubMed  Google Scholar 

  24. Londero F, Grossi W, Morelli A et al (2020) Surgery versus stereotactic radiotherapy for treatment of pulmonary metastases. A systematic review of literature. Future Sci OA 6:FSO471

    Article  CAS  Google Scholar 

  25. Von Einem JC, Stintzing S, Modest DP, Wiedemann M, Furweger C, Muacevic A (2020) Frameless single robotic radiosurgery for pulmonary metastases in colorectal cancer patients. Cureus 12:e7305

    PubMed  PubMed Central  Google Scholar 

  26. Khadige M, Salleron J, Marchesi V, Oldrini G, Peiffert D, Beckendorf V (2018) Cyberknife® stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months. J Thorac Dis 10:4976–4984

    Article  Google Scholar 

  27. Mihai A, Mu Y, Armstrong J et al (2017) Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease. J Radiosurg SBRT 5:43–53

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, MediClin Robert Janker Klinik, Villenstr. 8, 53129, Bonn, Germany

    Ali Rashid,  Michael Pinkawa, Hathal Haddad, Horst Hermani & Susanne Temming

  2. Department of Interventional and Diagnostic Radiology and Neuroradiology, MediClin Robert Janker Klinik, Villenstr. 8, 53129, Bonn, Germany

    Andreas Schäfer, Peter Bischoff & Attila Kovács

Authors
  1. Ali Rashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Pinkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hathal Haddad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Horst Hermani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susanne Temming
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andreas Schäfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Bischoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Attila Kovács
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Pinkawa.

Ethics declarations

Conflict of interest

A. Rashid, M. Pinkawa, H. Haddad, H. Hermani, S. Temming, A. Schäfer, P. Bischoff and A. Kovács declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rashid, A., Pinkawa, M., Haddad, H. et al. Interstitial single fraction brachytherapy for malignant pulmonary tumours. Strahlenther Onkol 197, 416–422 (2021). https://doi.org/10.1007/s00066-021-01758-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-021-01758-5

Keywords

Search

Navigation